Literature DB >> 18216263

Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis.

F Thomas Wunderlich1, Tom Luedde, Stephan Singer, Marc Schmidt-Supprian, Julia Baumgartl, Peter Schirmacher, Manolis Pasparakis, Jens C Brüning.   

Abstract

Development of obesity-associated insulin resistance and diabetes mellitus type 2 has been linked to activation of proinflammatory pathways in the liver, leading to impaired insulin signal transduction. To further define the role of hepatic NF-kappaB activation in this process, we have analyzed glucose metabolism in mice with liver-specific inactivation of the NF-kappaB essential modulator gene (NEMO(L-KO) mice) exposed to a high-fat diet (HFD). These animals are protected from the development of obesity-associated insulin resistance, highlighting the importance of hepatic NF-kappaB activation in this context. However, hepatic NEMO deficiency synergizes with HFD in the development of liver steatosis as a consequence of decreased peroxisome proliferator-activated receptor (PPAR-alpha) and increased PPAR-gamma expression. Steatosis interacts with increased inflammation, causing elevated apoptosis in the livers of these mice under HFD. These changes result in liver tumorigenesis of NEMO(L-KO) mice under normal diet, a process that is largely aggravated when these mice are exposed to HFD. These data directly demonstrate the interaction of hepatic inflammation, dietary composition, and metabolism in the development of liver tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18216263      PMCID: PMC2234132          DOI: 10.1073/pnas.0707849104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver.

Authors:  K Beier; A Völkl; H D Fahimi
Journal:  FEBS Lett       Date:  1997-07-28       Impact factor: 4.124

2.  Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury.

Authors:  Tom Luedde; Ulrike Assmus; Torsten Wüstefeld; Andreas Meyer zu Vilsendorf; Tania Roskams; Mark Schmidt-Supprian; Klaus Rajewsky; David A Brenner; Michael P Manns; Manolis Pasparakis; Christian Trautwein
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

3.  Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.

Authors:  Dongsheng Cai; Minsheng Yuan; Daniel F Frantz; Peter A Melendez; Lone Hansen; Jongsoon Lee; Steven E Shoelson
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

4.  IKK-beta links inflammation to obesity-induced insulin resistance.

Authors:  Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

5.  Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma.

Authors:  Tom Luedde; Naiara Beraza; Vasileios Kotsikoris; Geert van Loo; Arianna Nenci; Rita De Vos; Tania Roskams; Christian Trautwein; Manolis Pasparakis
Journal:  Cancer Cell       Date:  2007-02       Impact factor: 31.743

6.  Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

Authors:  Yoko Yoshioka; Etsuko Hashimoto; Satoru Yatsuji; Hiroyuki Kaneda; Makiko Taniai; Katsutoshi Tokushige; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2004-12       Impact factor: 7.527

7.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer.

Authors:  Eli Pikarsky; Rinnat M Porat; Ilan Stein; Rinat Abramovitch; Sharon Amit; Shafika Kasem; Elena Gutkovich-Pyest; Simcha Urieli-Shoval; Eithan Galun; Yinon Ben-Neriah
Journal:  Nature       Date:  2004-08-25       Impact factor: 49.962

8.  IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance.

Authors:  G S Hotamisligil; P Peraldi; A Budavari; R Ellis; M F White; B M Spiegelman
Journal:  Science       Date:  1996-02-02       Impact factor: 47.728

9.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers.

Authors:  H Keller; C Dreyer; J Medin; A Mahfoudi; K Ozato; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

10.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

Authors:  G S Hotamisligil; P Arner; J F Caro; R L Atkinson; B M Spiegelman
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more
  54 in total

1.  Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity.

Authors:  René L Jacobs; Yang Zhao; Debby P Y Koonen; Torunn Sletten; Brian Su; Susanne Lingrell; Guoqing Cao; David A Peake; Ming-Shang Kuo; Spencer D Proctor; Brian P Kennedy; Jason R B Dyck; Dennis E Vance
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.

Authors:  Y-S Lee; M-S Park; J-S Choung; S-S Kim; H-H Oh; C-S Choi; S-Y Ha; Y Kang; Y Kim; H-S Jun
Journal:  Diabetologia       Date:  2012-06-22       Impact factor: 10.122

3.  TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.

Authors:  Sayaka Inokuchi-Shimizu; Eek Joong Park; Yoon Seok Roh; Ling Yang; Bi Zhang; Jingyi Song; Shuang Liang; Michael Pimienta; Koji Taniguchi; Xuefeng Wu; Kinji Asahina; William Lagakos; Mason R Mackey; Shizuo Akira; Mark H Ellisman; Dorothy D Sears; Jerrold M Olefsky; Michael Karin; David A Brenner; Ekihiro Seki
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

Review 4.  Dissociating fatty liver and diabetes.

Authors:  Zheng Sun; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2012-10-05       Impact factor: 12.015

Review 5.  Mechanisms for insulin resistance: common threads and missing links.

Authors:  Varman T Samuel; Gerald I Shulman
Journal:  Cell       Date:  2012-03-02       Impact factor: 41.582

Review 6.  Cell penetrating peptide inhibitors of nuclear factor-kappa B.

Authors:  J S Orange; M J May
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

7.  Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes.

Authors:  Sebastián Mas; Roxana Martínez-Pinna; Jose Luis Martín-Ventura; Raul Pérez; Dulcenombre Gomez-Garre; Alberto Ortiz; Arturo Fernandez-Cruz; Fernando Vivanco; Jesús Egido
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

8.  Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance.

Authors:  Jan Mauer; Bhagirath Chaurasia; Leona Plum; Thomas Quast; Brigitte Hampel; Matthias Blüher; Waldemar Kolanus; C Ronald Kahn; Jens C Brüning
Journal:  PLoS Genet       Date:  2010-05-06       Impact factor: 5.917

9.  Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways.

Authors:  Xu-qiang Nie; Huai-hong Chen; Jian-yong Zhang; Yu-jing Zhang; Jian-wen Yang; Hui-jun Pan; Wen-xia Song; Ferid Murad; Yu-qi He; Ka Bian
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

10.  Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program.

Authors:  Marijana Radonjic; Jorn R de Haan; Marjan J van Erk; Ko Willems van Dijk; Sjoerd A A van den Berg; Philip J de Groot; Michael Müller; Ben van Ommen
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.